Zeta Surgical, a Boston-based company, received FDA clearance on July 10, 2026 for a robotic TMS navigation system, classified as a Class II stereotaxic instrument. It is intended to make TMS delivery for treatment-resistant depression more precise and repeatable.
The system uses AI and computer vision to track patient movement during a session and automatically adjusts coil position so stimulation stays on target. Zeta says it tested accuracy and usability with Harvard Medical School and the University of Cambridge, but no specific clinical data were disclosed.
This follows a May 2026 clearance of Zeta's navigation technology for neurosurgical guidance. Coil placement drift during a session is a known practical limit in TMS, so robotic positioning is a notable development, though whether it improves patient outcomes has yet to be shown.
Source
Reporting based on coverage from Medical Device Network. This article is editorial summary intended for general information; it is not medical advice.
